Opthea Limited (NASDAQ:OPT - Free Report) - Analysts at Leerink Partnrs lowered their FY2024 EPS estimates for shares of Opthea in a research note issued on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($2.15) per share for the year, down from their prior estimate of ($1.70). The consensus estimate for Opthea's current full-year earnings is ($2.46) per share. Leerink Partnrs also issued estimates for Opthea's FY2025 earnings at ($1.20) EPS and FY2026 earnings at ($0.90) EPS.
Opthea Trading Down 1.8 %
Shares of OPT stock traded down $0.07 during mid-day trading on Friday, reaching $3.83. The company's stock had a trading volume of 8,792 shares, compared to its average volume of 25,810. Opthea has a 1-year low of $1.60 and a 1-year high of $4.42. The firm's 50-day moving average is $3.47 and its two-hundred day moving average is $2.67.
Institutional Investors Weigh In On Opthea
Hedge funds have recently made changes to their positions in the company. Barclays PLC acquired a new stake in shares of Opthea during the 1st quarter worth about $26,000. OLD Mission Capital LLC acquired a new stake in shares of Opthea during the 4th quarter worth about $36,000. Finally, Regal Partners Ltd increased its position in shares of Opthea by 1.0% during the 2nd quarter. Regal Partners Ltd now owns 2,914,577 shares of the company's stock worth $8,161,000 after purchasing an additional 29,777 shares in the last quarter. Institutional investors and hedge funds own 55.95% of the company's stock.
Opthea Company Profile
(
Get Free Report)
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Further Reading
Before you consider Opthea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.
While Opthea currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
